Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 697 to 702 of 702 entries
Sorted by: Best Match Show Resources per page
Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.

Oncology

Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Kajiwara A, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Koga H, Torimura T.
PMID: 34518483
Oncology. 2021;99(12):756-765. doi: 10.1159/000518612. Epub 2021 Sep 08.

Background & Aims: Intermediate hepatocellular carcinoma (HCC) treatment has become complicated due to the development of various molecular-targeted agents (MTAs). We aimed to determine whether the administration of MTAs in patients with intermediate-stage HCC contributed to the prevention of...

Cite
Shimose S, Iwamoto H, Tanaka M, et al. Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology. 2021;99(12):756-765doi: 10.1159/000518612.
Shimose, S., Iwamoto, H., Tanaka, M., Niizeki, T., Shirono, T., Kajiwara, A., Noda, Y., Kamachi, N., Okamura, S., Nakano, M., Kuromatsu, R., Kawaguchi, T., Koga, H., & Torimura, T. (2021). Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology, 99(12), 756-765. https://doi.org/10.1159/000518612
Shimose, Shigeo, et al. "Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival." Oncology vol. 99,12 (2021): 756-765. doi: https://doi.org/10.1159/000518612
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Kajiwara A, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Koga H, Torimura T. Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology. 2021;99(12):756-765. doi: 10.1159/000518612. Epub 2021 Sep 08. PMID: 34518483.
Copy Download .nbib Format: NLM
Development of an Add-on .

Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine

Kajiwara M, Haishi T, Prananto D, Sasaki S, Kaseda R, Narita I, Terada Y.
PMID: 34897148
Magn Reson Med Sci. 2021 Dec 10; doi: 10.2463/mrms.tn.2021-0094. Epub 2021 Dec 10.

No abstract available.

Cite
Kajiwara M, Haishi T, Prananto D, et al. Development of an Add-on . Magn Reson Med Sci. 2021;doi: 10.2463/mrms.tn.2021-0094.
Kajiwara, M., Haishi, T., Prananto, D., Sasaki, S., Kaseda, R., Narita, I., & Terada, Y. (2021). Development of an Add-on . Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, . https://doi.org/10.2463/mrms.tn.2021-0094
Kajiwara, Michiru, et al. "Development of an Add-on ." Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine vol. (2021). doi: https://doi.org/10.2463/mrms.tn.2021-0094
Kajiwara M, Haishi T, Prananto D, Sasaki S, Kaseda R, Narita I, Terada Y. Development of an Add-on . Magn Reson Med Sci. 2021 Dec 10; doi: 10.2463/mrms.tn.2021-0094. Epub 2021 Dec 10. PMID: 34897148.
Copy Download .nbib Format: NLM
Trends in voluntary vaccination coverage in a Japanese city.

Pediatrics international : official journal of the Japan Pediatric Society

Hoshina T, Kawase M, Watanabe S, Shibahara J, Kojiro M, Miyake T, Sakaguchi Y, Kajiwara Y, Kusuhara K.
PMID: 33780596
Pediatr Int. 2021 Dec;63(12):1466-1471. doi: 10.1111/ped.14712. Epub 2021 Nov 08.

BACKGROUND: Large numbers of patients with diseases preventable by voluntary vaccines have been reported in Japan. However, it is difficult to analyze the impact of voluntary vaccination on disease prevention, as governments do not aggregate the number of recipients...

Cite
Hoshina T, Kawase M, Watanabe S, et al. Trends in voluntary vaccination coverage in a Japanese city. Pediatr Int. 2021;63(12):1466-1471doi: 10.1111/ped.14712.
Hoshina, T., Kawase, M., Watanabe, S., Shibahara, J., Kojiro, M., Miyake, T., Sakaguchi, Y., Kajiwara, Y., & Kusuhara, K. (2021). Trends in voluntary vaccination coverage in a Japanese city. Pediatrics international : official journal of the Japan Pediatric Society, 63(12), 1466-1471. https://doi.org/10.1111/ped.14712
Hoshina, Takayuki, et al. "Trends in voluntary vaccination coverage in a Japanese city." Pediatrics international : official journal of the Japan Pediatric Society vol. 63,12 (2021): 1466-1471. doi: https://doi.org/10.1111/ped.14712
Hoshina T, Kawase M, Watanabe S, Shibahara J, Kojiro M, Miyake T, Sakaguchi Y, Kajiwara Y, Kusuhara K. Trends in voluntary vaccination coverage in a Japanese city. Pediatr Int. 2021 Dec;63(12):1466-1471. doi: 10.1111/ped.14712. Epub 2021 Nov 08. PMID: 33780596.
Copy Download .nbib Format: NLM
ASO Visual Abstract: Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer.

Annals of surgical oncology

Nagata K, Shinto E, Shiraishi T, Yamadera M, Kajiwara Y, Mochizuki S, Okamoto K, Einama T, Kishi Y, Ueno H.
PMID: 34386916
Ann Surg Oncol. 2021 Dec;28:617. doi: 10.1245/s10434-021-10541-w.

No abstract available.

Cite
Nagata K, Shinto E, Shiraishi T, et al. ASO Visual Abstract: Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer. Ann Surg Oncol. 2021;28:617doi: 10.1245/s10434-021-10541-w.
Nagata, K., Shinto, E., Shiraishi, T., Yamadera, M., Kajiwara, Y., Mochizuki, S., Okamoto, K., Einama, T., Kishi, Y., & Ueno, H. (2021). ASO Visual Abstract: Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer. Annals of surgical oncology, 28617. https://doi.org/10.1245/s10434-021-10541-w
Nagata, Ken, et al. "ASO Visual Abstract: Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer." Annals of surgical oncology vol. 28 (2021): 617. doi: https://doi.org/10.1245/s10434-021-10541-w
Nagata K, Shinto E, Shiraishi T, Yamadera M, Kajiwara Y, Mochizuki S, Okamoto K, Einama T, Kishi Y, Ueno H. ASO Visual Abstract: Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer. Ann Surg Oncol. 2021 Dec;28:617. doi: 10.1245/s10434-021-10541-w. PMID: 34386916.
Copy Download .nbib Format: NLM
Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.

Scientific reports

Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F.
PMID: 34754037
Sci Rep. 2021 Nov 09;11(1):21992. doi: 10.1038/s41598-021-01455-4.

Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical for the generation of CD8

Cite
Yokoi T, Oba T, Kajihara R, et al. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep. 2021;11(1):21992doi: 10.1038/s41598-021-01455-4.
Yokoi, T., Oba, T., Kajihara, R., Abrams, S. I., & Ito, F. (2021). Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Scientific reports, 11(1), 21992. https://doi.org/10.1038/s41598-021-01455-4
Yokoi, Toshihiro, et al. "Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer." Scientific reports vol. 11,1 (2021): 21992. doi: https://doi.org/10.1038/s41598-021-01455-4
Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep. 2021 Nov 09;11(1):21992. doi: 10.1038/s41598-021-01455-4. PMID: 34754037; PMCID: PMC8578367.
Copy Download .nbib Format: NLM
Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise.

International journal of ophthalmology

Kakihara S, Hirano T, Imai A, Kurenuma T, Chiku Y, Murata T.
PMID: 33747814
Int J Ophthalmol. 2021 Mar 18;14(3):388-392. doi: 10.18240/ijo.2021.03.09. eCollection 2021.

AIM: To evaluate the effectiveness of micropulse laser trabeculoplasty (MLT) for eyes with open angle glaucoma (OAG) under maximal tolerable glaucoma eyedrops and to assess the effect of expertise performing MLT on its clinical effectiveness.METHODS: Medical records of 42...

Cite
Kakihara S, Hirano T, Imai A, et al. Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. Int J Ophthalmol. 2021;14(3):388-392doi: 10.18240/ijo.2021.03.09.
Kakihara, S., Hirano, T., Imai, A., Kurenuma, T., Chiku, Y., & Murata, T. (2021). Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. International journal of ophthalmology, 14(3), 388-392. https://doi.org/10.18240/ijo.2021.03.09
Kakihara, Shinji, et al. "Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise." International journal of ophthalmology vol. 14,3 (2021): 388-392. doi: https://doi.org/10.18240/ijo.2021.03.09
Kakihara S, Hirano T, Imai A, Kurenuma T, Chiku Y, Murata T. Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. Int J Ophthalmol. 2021 Mar 18;14(3):388-392. doi: 10.18240/ijo.2021.03.09. eCollection 2021. PMID: 33747814; PMCID: PMC7930551.
Copy Download .nbib Format: NLM
Showing 697 to 702 of 702 entries